Live Breaking News & Updates on Trishula Therapeutics

Stay updated with breaking news from Trishula therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Form 8-K HUMANIGEN, INC For: Oct 19

Form 8-K HUMANIGEN, INC For: Oct 19
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , Kevin Xie , Ken Trbovich , Burroughs Wellcome , Cameron Durrant , John Hohneker , Gettysburg College , University Of North Carolina At Chapel Hill , Humanigen Inc , Healthcare Holdings For Fosun Group , Biotheryx Inc , Global Head Of Development , Tianjin University , University Of Medicine , Aravive Inc , City University Of New York , Cygnal Therapeutics Inc , Wharton School Of The University Pennsylvania , Company Board Of Directors The , Wall Street , Elects John Hohneker , Cygnal Therapeutics , Evelo Biosciences , Trishula Therapeutics , Senior Vice President ,

Durability of lifileucel linked to duration of immune checkpoint inhibitor use in melanoma

Durability of lifileucel linked to duration of immune checkpoint inhibitor use in melanoma
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United States , Merck Serono , Pierre Fabre , Roche Genentech , James Mg Larkin , Jasona Chesney , Jasonj Luke , Serono Incyte , Astellas Pharma , Immatics Incyte , Imugene Incyte , Iovance Biotherapeutics , Spring Bank , University Of Pittsburgh School Medicine , Bristol Myers Squibb , University Of Louisville , Checkmate Pharmaceuticals , Cstone Pharmaceuticals , Corvus Pharmaceuticals , Nektar Therapeutics , James Graham Brown Cancer Center , Hillman Cancer Center , Achilles Therapeutics , Boston Biomedical , Merck Sharp , Royal Marsden ,

BioSpace Movers & Shakers, May 21

Published: May 21, 2021
By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation. ....

United States , Stephen Basso , Inozyme Pharma , Phelps Mcnamara , R Michael Carruthers , Synageva Biopharma , Peter Pechan , Sierk Poetting , Jens Hosltein , Lucio Tozzi , Bradley Glover , Bristol Myers Squibb , Mark Pennesi , Guy Levy , Evelo Biosciences , Tyler Ralston , Johna Hohneker , Aeglea Biotherapeutics , Sigurdc Kirk , Irena Melnikova , Christian Weyer , Iveric Bio , Umoja Biopharma , Robert Doebele , Stephen Boyer , Timothy Noyes ,

Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
Trishula TherapeuticsJanuary 21, 2021 GMT
Trishula Continues to Advance Development of TTX-030 in collaboration with AbbVie
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) Today Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, announced the appointment of Anil Singhal, Ph.D., MBA, as Chief Executive Officer, effective immediately. Dr. Singhal will also serve on the Trishula Board of Directors.
“The Board of Directors of Trishula Therapeutics is thrilled to bring Anil to the company with his stellar track record in advancing novel oncology therapies from early clinical development through to approval,” said Luke Evnin, Ph.D., Chairman of Trishula’s Board of Directors. “We have ....

Luke Evnin , Adicet Bio , Janet Graesser , Trishula Therapeutics Inc , Adjunct Associate Professor At University Of Washington , Trishula Continues To Advance Development , Oncoresponse Inc , Early Oncology Development At Abbvie , Advance Development , Trishula Therapeutics , Anil Singhal , Chief Executive Officer , Trishula Board , Canaan Partners , Vice President , Early Oncology Development , Abbvie Redwood City , Assistant Research Professor , Mount Sinai School , Adjunct Associate Professor , Executive Changes , Products And Services , Health Care Industry , Corporate News , Corporate Management , New Products And Services ,